International expert in targeted nanoparticles. Formerly CSO of Merimmack Pharma and current CSO of Akagera Medicines.
Dr. Salpeter has deep experience in developing and bringing new biotechnologies to market. He previously served as Co-Founder and CTO at Curesponse, a precision cancer medicine company. Prior to that he was Chief Scientist and VP Business Development at Sight Diagnostics. Dr. Salpeter holds a Ph.D in Biochemistry from the Hebrew University and performed post-doctoral studies at the Institute for Drug Research, the Hebrew University School of Pharmacy.
Dr. Julian Adams is currently the CSO of Stand Up 2 Cancer and was previously CEO of Gamida Cell following his role as President and Chief Scientific Officer at Clal Biotechnology Industries (CBI). Before joining CBI, he served as the President of R&D at Infinity Pharmaceuticals, where he built and led the company’s R&D efforts. Julian served as Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals, where he played a key role in the discovery of Velcade® (bortezomib. Earlier in his career, he was credited with discovering Viramune® (nevirapine) for HIV at BI. He is a world recognized expert in drug development and R&D.